LÄKEMEDELSVERKET
SWEDISH MEDICAL PRODUCTS AGENCY

Summary Public Assessment Report

Zubatmin
(nicotinamide, glucose monohydrate, ascorbic acid, thiamine hydrochloride, riboflavin sodium phosphate, pyridoxine hydrochloride)

SE/H/2523/01/DC

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.lakemedelsverket.se E-mail: registrator@lakemedelsverket.se

Summary Public Assessment Report

Zubatmin
nicotinamide, glucose monohydrate, ascorbic acid, thiamine hydrochloride, riboflavin sodium phosphate, pyridoxine hydrochloride

Concentrate for solution for infusion.

This is a summary of the public assessment report (PAR) for Zubatmin. It explains how the assessment was made and why the authorisation was recommended as well as the conditions of use. It is not intended to provide practical advice on how to use the product.

For practical information about the use of the product, patients should read the package leaflet or contact their doctor or pharmacist.

What is Zubatmin and what is it used for?

The product is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance.

The reference medicine for the product is Pabrinex.

Zubatmin provides additional thiamine hydrochloride, riboflavin, pyridoxine hydrochloride and nicotinamide (B vitamins); ascorbic acid (vitamin C); and glucose to correct deficiencies that may have occurred:
- in alcoholism
- through unbalanced diet (malnutrition) or
- poor absorption (malabsorption) of the water soluble vitamins B and C

How does Zubatmin work?

Vitamins B and C are important for a number of bodily functions including releasing energy from food and in the formation of healthy skin, bones and teeth.

This medicine will be given to you by a healthcare professional by drip infusion into a vein.

How is Zubatmin used?

The pharmaceutical form is concentrate for solution for infusion.

Please read section 3 of the package leaflet for detailed information on dosing recommendations, the route of administration, and the duration of treatment.

The medicine can only be obtained with a prescription in Sweden.

What benefits of Zubatmin have been shown in studies?

No additional studies were needed as the product is considered to be bioequivalent to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the possible side effects from Zubatmin?

For the full list of side effects, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why is Zubatmin approved?

It was concluded that, in accordance with EU requirements, the product has been shown to have comparable quality and is considered to be similar to the reference medicine. Therefore, the Swedish Medical Products Agency decided that, as for Pabrinex, the benefits are greater than its risks and recommended that it can be approved for use.

What measures are being taken to ensure the safe and effective use of Zubatmin?

A risk management plan has been developed to ensure that the product is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously as well.

For more details, please see the full PAR for Zubatmin on the following website: MRI - Home.

Other information about Zubatmin

The full PAR for Zubatmin can be found on the following website: MRI - Home. For more information about treatment with Zubatmin, please read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in 2025-11.